Antinuclear Antibody Test Market is Thriving USD 2.36 Billion Revenue by 2025
Rising adoption of ANA test coupled with government initiatives to treat autoimmune disorders is likely to drive the market. Furthermore, rising incidence of autoimmune disorders is projected to fuel the growth.
94105(firmenpresse) - The global antinuclear antibody test market size is expected to reach USD 2.36 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 12.5% over the forecast period. Rising adoption of ANA test coupled with government initiatives to treat autoimmune disorders is likely to drive the market. Furthermore, rising incidence of autoimmune disorders is projected to fuel the growth.
Antinuclear Antibody (ANA) testing is an important tool to diagnose and manage autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis. According to the Lupus Foundation of America, at least 5 million people globally and around 1.5 million people in U.S. have a form of lupus. Around 16,000 new cases are registered every year. The disease mostly affects women of childbearing age. SLE accounts for almost 70% of all cases of lupus. The high prevalence of autoimmune disorders is one of the factors driving the market.
Extension of ANA from a test for SLE to a test for any autoimmune diseases has boosted the usage of antinuclear antibody testing. An increase in ANA demand may also be due to the factors such as expanded role of primary care physicians in healthcare delivery systems. In addition, rising R&D activities and government initiatives regarding early diagnosis of autoimmune disorders have triggered the demand for ANA tests.
Access Research Report of Antinuclear Antibody Test Market (at) https://www.grandviewresearch.com/industry-analysis/antinuclear-antibody-ana-test-market
Further key findings from the study suggest:
Reagents and assay kits was the largest segment in 2017. It is likely to witness fastest growth over the forecast period due to wide usage and rise in a number of reagent rental agreements
Immunofluorescence assay led the market in terms of market share in 2017 owing to superior sensitivity compared to other available techniques
ELISA is expected to be the fastest growing segment over the forecast period. Increasing adoption of these tests is attributed to easy automation and handling without high level of operator skill
Rheumatoid arthritis segment is projected to hold largest market share, mainly due to high prevalence of the disease
North America was the largest region in terms of revenue in 2017, followed by Europe. Both are the most well-established regions in terms of the adoption of ANA testing and make up most of the existing market
Asia Pacific is likely to be the fastest growing region over the forecast period due to unmet clinical needs and need for better diagnosis. Rising government initiatives and clinical research activities for advanced diagnostics are expected to further fuel growth
Key players operating in the antinuclear antibody test market are Thermo Fisher Scientific Inc.; Alere Inc.; Bio-Rad Laboratories; Trinity Biotech PLC; Zeus Scientific, Inc.; Inova Diagnostics; Immuno Concepts; Erba Diagnostics, Inc.; Euroimmun AG; and Antibodies Inc.
Key companies are adopting R&D, geographic expansion, and collaborations to gain market share.
Grand View Research has segmented the global antinuclear antibody test market on the basis of product, technique, application, end use, and region:
Antinuclear Antibody Test Product Outlook (Revenue, USD Million, 2014 - 2025)
Reagents & Assay Kits
Systems
Software & Services
Antinuclear Antibody Test Technique Outlook (Revenue, USD Million, 2014 - 2025)
ELISA
Immunofluorescence Assay
Multiplex Assay
Antinuclear Antibody Test Application Outlook (Revenue, USD Million, 2014 - 2025)
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Sjogren’s Syndrome
Scleroderma
Others
Antinuclear Antibody Test End-use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals
Clinical Laboratories
Physician Office Laboratories
Others
Antinuclear Antibody Test Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
US.
Canada
Europe
UK.
Germany
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
MEA
South Africa
Access Press Release of Antinuclear Antibody Test Market(at) https://www.grandviewresearch.com/press-release/global-antinuclear-antibody-ana-test-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2019 - 10:25 Uhr
Sprache: Deutsch
News-ID 602185
Anzahl Zeichen: 5500
contact information:
Contact person: Sonali Kulkarni
Town:
San Francisco
Phone: 14153490058
Kategorie:
Healthcare & Medical
Typ of Press Release: please
type of sending: don't
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Antinuclear Antibody Test Market is Thriving USD 2.36 Billion Revenue by 2025"
steht unter der journalistisch-redaktionellen Verantwortung von
Grand View Research Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
